ARTICLE | Preclinical News
Engineered Cas9 derivatives avoid T cell reactivity
April 25, 2019 1:05 PM UTC
Arizona State University researchers have engineered Cas9 to avoid pre-existing immunity against the bacterial protein, a safety concern for in vivo CRISPR-Cas9 gene editing.
Samira Kiani, an ASU assistant professor who co-led the study, told BioCentury she believes her group is the first to demonstrate that the approach of removing some immunogenic epitopes could alleviate cellular immunity against Cas9...
BCIQ Company Profiles
BCIQ Target Profiles